Crism Therapeutics (LSE:CRTX) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Crism Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Crism Therapeutics's Free Cash Flow for the six months ended in Jun. 2024 was £-0.48 Mil. Crism Therapeutics's Revenue for the six months ended in Jun. 2024 was £0.00 Mil. Therefore, Crism Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Crism Therapeutics's current FCF Yield % is -15.30%.

The historical rank and industry rank for Crism Therapeutics's FCF Margin % or its related term are showing as below:

LSE:CRTX' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1532.26
Current: 1532.26

During the past 13 years, the highest FCF Margin % of Crism Therapeutics was 1532.26%. The lowest was 0.00%. And the median was 0.00%.

LSE:CRTX's FCF Margin % is ranked better than
99.1% of 999 companies
in the Biotechnology industry
Industry Median: -120.51 vs LSE:CRTX: 1532.26

Crism Therapeutics FCF Margin % Historical Data

The historical data trend for Crism Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crism Therapeutics FCF Margin % Chart

Crism Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Crism Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial															-	-	-332.26	-	-

Competitive Comparison of Crism Therapeutics's FCF Margin %

For the Biotechnology subindustry, Crism Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crism Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crism Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Crism Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Crism Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Crism Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2.174	/	0
	=	%

Crism Therapeutics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-0.475	/	0
	=	%

Crism Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Crism Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Crism Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crism Therapeutics Corp (LSE:CRTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB

Website

https://www.crismtherapeutics.com

Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.

Crism Therapeutics Headlines

No Headlines